Nabi Biopharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1967-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.nabi.com
A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 260
- Registration Number
- NCT01375933
- Locations
- 🇺🇸
NicVAX Investigator, Rockville, Maryland, United States
A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT01304810
- Locations
- 🇺🇸
NicVAX Investigator, Seattle, Washington, United States
Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT01178346
- Locations
- 🇺🇸
NicVAX, Indianapolis, Indiana, United States
🇺🇸NicVAX Investigator, Madison, Wisconsin, United States
A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-12
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 1000
- Registration Number
- NCT01102114
- Locations
- 🇺🇸
NicVAX Investigator, Charleston, West Virginia, United States
NicVAX/Placebo as an Aid for Smoking Cessation
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 1000
- Registration Number
- NCT00836199
- Locations
- 🇺🇸
NicVAX Investigator, Madison, Wisconsin, United States
Antibody and Safety Study of 6 Doses of NicVAX in Smokers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-01-21
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT00598325
- Locations
- 🇺🇸
Accelovance, Inc., Rockville, Maryland, United States
Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT00218413
- Locations
- 🇳🇱
University of Maastricht, Maastricht, Netherlands
StaphVAX in Cardiovascular Surgery Patients
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-01-04
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT00211913
- Locations
- 🇺🇸
Clinical Research Associates of Tidewater, Norfolk, Virginia, United States
Evaluation of Consistency of StaphVAX Manufacturing Lots
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 354
- Registration Number
- NCT00211991
- Locations
- 🇺🇸
Vanderbuilt University, Nashville, Tennessee, United States
StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-01-04
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 67
- Registration Number
- NCT00211965
- Locations
- 🇬🇧
National Royal Orthopaedic Hospital, Stanmore, Middlesex, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath